Denmark-based AI immunology company Evaxion Biotech has entered into a clinical trial and supply agreement with Merck & Co’s subsidiary Kenilworth (known as MSD outside the US and Canada) for the clinical trial of melanoma therapies.
Evaxion will conduct a Phase 2b clinical trial—expected to launch by the end of 2021—of its cancer immunotherapy EVX-01, combined with MSD’s anti-PD-1 (a protein found in T cells) therapy Keytruda, on patients with metastatic melanoma stages 3 and 4. MSD will supply the required Keytruda and continue collaborating as the study data evolves.
Evaxion believes the partnership will improve the treatment and strengthen the evidence surrounding Evaxion’s platform and pipeline. It will also reduce the costs incurred to conduct the trial. The Phase 1/2a trial of EVX-01 to treat melanoma is currently ongoing.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.